<p><span class="legendSpanClass"><span class="xn-location">BEIJING</span> and <span class="xn-location">SHANGHAI</span> and <span class="xn-location">BOSTON</span></span>, <span class="legendSpanClass"><span class="xn-chron">Aug. 30, 2025</span></span> /PRNewswire/ --&nbsp;Jacobio Pharma (1167.HK) today announced its interim results for the six months ended <span class="xn-chron">June 30, 2025</span>.</p>  <p>During the reporting period, the Company achieved revenue of <span class="xn-money">RMB45.7 million</span>, representing a 100% increase compared with the same period in 2024. Research and development (R&amp;D) expenses amounted to &nbsp;RMB93.2 million. The net loss for the first half of 2025 was <span class="xn-money">RMB59.0 million</span>, &nbsp;narrowing by 65.1% compared with the same period in 2024. As of <span class="xn-chron">June 30, 2025</span>, Jacobio maintained cash and bank balances, and investments in capital protected structure deposits, totaling <span class="xn-money">RMB1,07billion</span>, along with <span class="xn-money">RMB270 million</span> bank credit available which provides sufficient and stable liquidity to support our R&amp;D activities.</p>  <p>Dr. Yinxiang Wang, Chairman and Chief Executive Officer of Jacobio, said: &quot;In the first half of 2025, we reached an important milestone with the&nbsp; approval and launch of Glecirasib in <span class="xn-location">China</span>. Through our collaboration with business partners, we significantly alleviated the pressure of R&amp;D investment, enabling the Company to focus resources on advancing our pan-KRAS inhibitor and ADC pipeline. Looking forward, we&nbsp; remain committed &nbsp;to a transformative innovation &nbsp;strategy, working hand in hand with global partners to accelerate the development of breakthrough therapies and deliver benefits to more cancer patients.&quot;</p>  <p>Accelerated Progress in Core Programs</p>  <p>JAB-23E73 (pan-KRAS inhibitor):</p>  <ul type="disc">   <li>The dose-escalation portion of the phase I trials are onging in <span class="xn-location">China</span> and the U.S, respectively.</li>   <li>Safety profile: low incidence of skin toxicity (rash observed in 10%, all Grade 1) no Grade ?? liver toxicity reported to date.</li>   <li>Favorable PK with predicted exposure.</li>   <li>Multiple partial responses have been observed to date.</li>   <li>Preclinical data to be presented at the AACR-NCI-EORTC International Conference in <span class="xn-chron">October 2025</span>.</li>   <li>Phase I results readout expected in the first half of 2026.</li>  </ul>  <p>JAB-BX600 (First-in-class EGFR-KRAS G12Di ADC):</p>  <ul type="disc">   <li>This program uses a highly potent KRAS G12D inhibitor as the payload.</li>   <li>The candidate demonstrates picomolar (pM)-level cellular activity, compared with nanomolar (nM) typically achieved by oral small molecules.</li>   <li>Unlike oral small molecules usually achieve tumor drug concentrations 1??0x higher than plasma levels, the JAB-BX 600 delivers a KRAS G12D inhibitor at 1,000 x higher in tumor, resulting in a substantially wider therapeutic window.</li>   <li>The KRAS G12D inhibitor and EGFR antibody have synergistic effect and durable anti-tumor activity.</li>   <li>IND submission planned for the second half of 2026.</li>  </ul>  <p>Glecirasib (JAB-21822, KRAS G12C inhibitor):</p>  <ul type="disc">   <li>Approved by <span class="xn-location">China's</span> NMPA in <span class="xn-chron">May 2025</span> for ??L KRAS G12C mutant NSCLC, successfully launched in <span class="xn-location">China</span>.</li>   <li>Triggered a <span class="xn-money">RMB50 million</span> milestone payment in addition to the <span class="xn-money">RMB200 million</span> upfront received in 2024.</li>   <li>The full second-line NSCLC dataset has been published in Nature Medicine (Impact Factor: 50).</li>   <li>Phase I/II data for the combination with <span class="xn-money">SHP2</span> inhibitor has been accepted by a top-tier academic journal, with publication&nbsp;<span>expected in H2 2025.</span></li>  </ul>  <p>Sitneprotafib (JAB-3312, <span class="xn-money">SHP2</span> inhibitor):</p>  <ul type="disc">   <li>Ongoing Phase III registration trial in combination with Glecirasib as first-line NSCLC treatment in <span class="xn-location">China</span>.</li>   <li>Translational research published in Clinical Cancer Research (Impact Factor: 10.2), demonstrating significant synergy with Glecirasib.</li>  </ul>  <p>JAB-BX467 (HER2-STING iADC):</p>  <ul type="disc">   <li>A HER2-targeted ADC carrying a STING agonist, designed to convert &quot;cold tumors&quot; into &quot;hot tumors&quot; and address the 70% of patients unresponsive to PD-1 inhibitors.</li>   <li>Currently in IND-enabling stage, with IND filing planned for H2 2026.</li>  </ul>  <p>&nbsp;</p>